Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Oxtoby | $537,733 | $0 | $0 | $1,687,076 | $344,306 | $0 | $0 | $2,569,115 |
| President and Chief Executive Officer | ||||||||
| Matthew Feinsod | 457,732 | 0 | 0 | 1,008,403 | 207,636 | 0 | 0 | 1,673,771 |
| Chief Medical Officer | ||||||||
| Brett Hagen | 397,301 | 67,814 | 0 | 295,417 | 121,512 | 0 | 557,130 | 1,439,174 |
| Chief Accounting Officer | ||||||||
| Vikas Sinha | 81,106 | 0 | 0 | 0 | 0 | 0 | 1,019,848 | 1,100,954 |
| AlloVir's Former Chief Executive Officer, President and Chief Financial Officer | ||||||||
| Matthew Gall | 80,833 | 0 | 0 | 949,279 | 34,495 | 0 | 0 | 1,064,607 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Andrew Oxtoby | $2,569,115 | $1,965,153 | — | +603,962 |
| Matthew Feinsod | 1,673,771 | — | — | — |
| Brett Hagen | 1,439,174 | 796,311 | — | +642,863 |
| Vikas Sinha | 1,100,954 | 544,400 | — | +556,554 |
| Matthew Gall | 1,064,607 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Matthew Feinsod | Option | — | — | — | — | — | $1,008,403 |
| Andrew Oxtoby | Option | — | — | — | — | — | 1,687,076 |
| Matthew Gall | Option | — | — | — | — | — | 949,279 |
| Brett Hagen | Option | — | — | — | — | — | 295,417 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Matthew Feinsod | $0 | $0 | $1,008,403 | 0.0% |
| Andrew Oxtoby | 0 | 0 | 1,687,076 | 0.0% |
| Matthew Gall | 0 | 0 | 949,279 | 0.0% |
| Brett Hagen | 0 | 0 | 295,417 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Feinsod | Option | 101,000 | 7.31 | — |
| Andrew Oxtoby | Option | 268,090 | 0.85 | — |
| Andrew Oxtoby | Option | 287,000 | 7.31 | — |
| Matthew Feinsod | Option | 20,160 | 0.85 | — |
| Brett Hagen | Option | 50,262 | 7.31 | — |
| Matthew Feinsod | Option | 52,913 | 7.31 | — |
| Matthew Gall | Option | 235,000 | 4.99 | — |
We believe that equity grants provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive officers and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 15,852,844 | 495,763 | 4,366 | 96.97% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | 96.97%a |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes (if any) will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David HallalIndependent · Board Chair · Compensation · Nominating/Governance | $140,000 | $0 | $104,430 | — | — | $244,430 |
| Morana Jovan-EmbiricosIndependent · Audit | 51,875 | 0 | 104,430 | — | — | 156,305 |
| Napoleone FerraraIndependent · Nominating/Governance · Newly elected | 33,000 | 0 | 104,430 | — | 13,663 | 151,093 |
| Samir PatelNot independent · Departed during FY | — | 0 | 104,430 | — | 44,000 | 148,430 |
| Leone PattersonIndependent · Audit (Chair) · Newly elected | 41,250 | 0 | 104,430 | — | — | 145,680 |
| Michael DybbsIndependent · Compensation (Chair) | 39,000 | 0 | 104,430 | — | — | 143,430 |
| Anthony P. AdamisIndependent · Audit | 35,625 | 0 | 104,430 | — | 1,850 | 141,905 |
| Srinivas AkkarajuIndependent · Nominating/Governance (Chair) | 36,000 | 0 | 104,430 | — | — | 140,430 |
| Jeffrey S. BornsteinIndependent · Departed during FY | 16,875 | 0 | — | — | — | 16,875 |
| Shawn TomaselloIndependent · Departed during FY | 13,750 | 0 | — | — | — | 13,750 |
| Derek AdamsIndependent · Departed during FY | 13,125 | 0 | — | — | — | 13,125 |
| Malcolm BrennerIndependent · Departed during FY | 12,500 | 0 | — | — | — | 12,500 |
| Juan VeraIndependent · Departed during FY | 10,000 | 0 | — | — | — | 10,000 |
| Andrew OxtobyEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $104,430 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $443,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $59,513 |
| Total cost of the board | $502,513 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kalaris Therapeutics | 2025 | Andrew Oxtoby | $537,733 | $0 | $1,687,076 | $344,306 | $2,569,115 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Andrew Oxtoby | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table” · page 28. As printed: 2,569,115. Filing ↗machine: r2 · c27 · span 295176–295185 |
| 2 | Section 01, Matthew Feinsod | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table” · page 28. As printed: 1,673,771. Filing ↗machine: t117 · r5 · c27 · span 301661–301670 |
| 3 | Section 01, Brett Hagen | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table” · page 28. As printed: 1,439,174. Filing ↗machine: span 312546–312555 |
| 4 | Section 01, Vikas Sinha | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table” · page 28. As printed: 1,100,954. Filing ↗machine: r8 · c26 · span 307794–307803 |
| 5 | Section 01, Matthew Gall | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table” · page 28. As printed: 1,064,607. Filing ↗machine: t117 · r7 · c27 · span 305646–305655 |
| 6 | Section 03, Matthew Feinsod Option | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t117 · r5 · c15 · span 300716–300725 |
| 7 | Section 03, Andrew Oxtoby Option | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t117 · r2 · c15 · span 294377–294386 |
| 8 | Section 03, Matthew Gall Option | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t117 · r7 · c15 · span 304694–304701 |
| 9 | Section 03, Brett Hagen Option | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t117 · r10 · c15 · span 311752–311759 |
| 10 | Section 07, pay ratio | 10-K | 2026-03-17 | 0001193125-26-110659 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, David Hallal | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 244,430. Filing ↗machine: t140 · r5 · c15 · span 406182–406189 |
| 12 | Section 08, Morana Jovan-Embiricos | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 156,305. Filing ↗machine: t140 · r6 · c15 · span 408957–408964 |
| 13 | Section 08, Napoleone Ferrara | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 151,093. Filing ↗machine: t140 · r12 · c15 · span 425492–425499 |
| 14 | Section 08, Samir Patel | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 148,430. Filing ↗machine: t140 · r13 · c15 · span 428236–428243 |
| 15 | Section 08, Leone Patterson | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 145,680. Filing ↗machine: t140 · r14 · c15 · span 431001–431008 |
| 16 | Section 08, Michael Dybbs | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 143,430. Filing ↗machine: t140 · r11 · c15 · span 422728–422735 |
| 17 | Section 08, Anthony P. Adamis | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 141,905. Filing ↗machine: t140 · r9 · c15 · span 417211–417218 |
| 18 | Section 08, Srinivas Akkaraju | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 140,430. Filing ↗machine: t140 · r10 · c15 · span 419987–419994 |
| 19 | Section 08, Jeffrey S. Bornstein | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 16,875. Filing ↗machine: t140 · r3 · c3 · span 398829–398835 |
| 20 | Section 08, Shawn Tomasello | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 13,750. Filing ↗machine: t140 · r7 · c3 · span 409866–409872 |
| 21 | Section 08, Derek Adams | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 13,125. Filing ↗machine: t140 · r2 · c3 · span 396079–396085 |
| 22 | Section 08, Malcolm Brenner | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 12,500. Filing ↗machine: t140 · r4 · c3 · span 401612–401618 |
| 23 | Section 08, Juan Vera | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 10,000. Filing ↗machine: t140 · r8 · c3 · span 412637–412643 |
| 24 | Section 08, Andrew Oxtoby | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001193125-26-257388 | Item 5.07 · say-on-pay result. As reported: 96.97% (votes for as printed: 15,852,844). Filing ↗ |
| 26 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 27 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 28 | Section 09b board cost (computed) | Computed | — | computed | Cash 443,000 + equity 0 + all other 59,513 = 502,513, summed across the director compensation table rows.machine: formula: Σ = 502,513 |
| 29 | Kalaris Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177362 | CEO total compensation as printed in Kalaris Therapeutics's own proxy. As printed: 2,569,115. Filing ↗machine: r2 · c27 · span 295176–295185 |